Clinical Trial Update: New Combination Inhaler (FlutiForm HFA MDI 100/10 µg and 250/10 µg) Versus Fluticasone and Formoterol Administered Alone, and Placebo in Patients With Moderate to Severe Asthma [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluated a new combination inhaler, FlutiForm HFA at two dose strengths (100/10 µg and 250/10 µg), against fluticasone propionate and formotero…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• FlutiForm HFA MDI 100/10 µg (fluticasone propionate/formoterol)
• FlutiForm HFA MDI 250/10 µg (fluticasone propionate/formoterol)
• Fluticasone propionate (Fluticasone propionate)
• Formoterol (formoterol)

Snippet

Sponsor: SkyePharma AG | Conditions: Asthma | Phase 3 | Status: COMPLETED